Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 596-598

  Taliani, Maria Rita ^a   Becattini, Cecilia ^a   Agnelli, Giancarlo ^a   Prandoni, Paolo ^b   Moia, Marco ^c   Bazzan, Mario ^d   Salvi, Rosa Maria ^e   Ageno, Walter ^f   Guazzaloca, Giuliana ^g   Imberti, Davide ^h   Silingardi, Mauro ⁱ   Poggio, Renzo ^j  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Unità di Ematologia e Malattie Trombotiche Cellini Humanitas   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Ospedale di Piacenza   (Italy)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j GALLIERA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; PROTEIN C; PROTEIN S;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTICLE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENCE RISK; RECURRENT DISEASE; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; THROMBOPHILIA; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 62749171823     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-07-0477     Document Type: Article

References (23)

1. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (Suppl I): I-9-I-16.
2. Weitz JI, Middeldorp S, Geerts W. et al. Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program 2004; 1: 424-438.
3. Van den Belt AGM, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-2232.
4. Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004; 110 (Suppl I): I-10-1-18.
5. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risk of recurrent idiopathic venous thromboembolism. Circulation 1995; 92; 2800-2802.
6. Rintelen C, Pabinger I, Knobl P, et al. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haem 1996; 75: 229-232.
7. Simioni P. Prandoni P. Leasing AWA, et al. The risk of recurrent venous thromboembolism in patients with anArg 506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
8. Eichinger S, Pabinger I, Stumpllen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-628.
9. Baglin C, Brown K, Luddington R, et al. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVL506Q) mutation: effect of warfarin and prediction by precipitating factors. Br J Haematol 1998; 100: 764-768.
10. Eichinger S, Stumpllen A, Hirschl M, et al. Hyper-homocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569.
11. De Stefano V, Martinelh I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
12. Lindmarker P. Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-689.
13. Kearon C, Gent M, Hirsh J, et al. A Comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
14. Meinardi JR, Middeldorp S, de Kamp PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116: 625-631.
15. Baglin T. Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
16. Santamaria MG, Agnelli G, Taliani MR, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005; 116: 301-306.
17. De Stefano V. Leone G, Mastrangelo S, et al. Clinical manifestations of inherited thrombophilia: a retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-358.
18. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
19. Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
20. Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haemaiologica 2007; 92: 1107-1114.
21. Young G, Becker S, During C, et al. Influence of the factor V G1691A mutation on symptomatic recurrent venous thromboembolism (VTE) in children: an international multicenter cohort study. J Thromb Haemost 2008; epub ahead of print.
22. Agnelli G, Prandoni P, Santamaria MG. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169.
23. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Int Med 2003; 139: 19-25.